The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
Open accessAbstract
Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies. COMFORT-II was a randomized (2:1), open-label phase 3 study in patients with myelofibrosis; patients randomized to BAT could crossover to ruxolitinib upon protocol-defined disease progression or after the primary end point, confounding long-term comparisons. At week 48, 28% (41/146) of patients randomized to ruxolitinib achieved ⩾35% decrease in spleen volume (primary end point) compared with no patients on BAT ( P <0.001). Among the 78 patients (53.4%) in the ruxolitinib arm who achieved ⩾35% reductions in spleen volume at any time, the probability of maintaining response was 0.48 (95% confidence interval (CI), 0.35–0.60) at 5 years (median, 3.2 years). Median overall survival was not reached in the ruxolitinib arm and was 4.1 years in the BAT arm. There was a 33% reduction in risk of death with ruxolitinib compared with BAT by intent-to-treat analysis (hazard ratio (HR)=0.67; 95% CI, 0.44–1.02; P =0.06); the crossover-corrected HR was 0.44 (95% CI, 0.18–1.04; P =0.06). There was no unexpected increased incidence of adverse events with longer exposure. This final analysis showed that spleen volume reductions with ruxolitinib were maintained with continued therapy and may be associated with survival benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Self-citationCervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationTefferi, A., & Vardiman, J. W. (2008) · Leukemia · doi:10.1038/sj.leu.2404955 · Cited by 1,002
Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 994
Self-citationQuintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
European consensus on grading bone marrow fibrosis and assessment of cellularity.
Thiele, J., Kvasnicka, H. M., Facchetti, F., Franco, V., van der Walt, J. D., & Orazi, A. (2005) · PubMed · Cited by 762
Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Self-citationCervantes, F., Vannucchi, A. M., Kiladjian, J.-J., Al-Ali, H. K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R. S., Passamonti, F., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485888 · Cited by 426
Self-citationRobins, J. M., & Tsiatis, A. A. (1991) · Communications in Statistics - Theory and Methods · doi:10.1080/03610929108830654 · Cited by 423
New mutations and pathogenesis of myeloproliferative neoplasms
Vainchenker, W., Delhommeau, F., Constantinescu, S. N., & Bernard, O. A. (2011) · Blood · doi:10.1182/blood-2011-02-292102 · Cited by 395
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.115840 · Cited by 334
Vannucchi, A. M., Kantarjian, H. M., Kiladjian, J.-J., Gotlib, J., Cervantes, F., Mesa, R. A., Sarlis, N. J., Peng, W., Sandor, V., Gopalakrishna, P., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.119545 · Cited by 260
Self-citationLevine, R. L., Belisle, C., Wadleigh, M., Zahrieh, D., Lee, S., Chagnon, P., Gilliland, D. G., & Busque, L. (2006) · Blood · doi:10.1182/blood-2005-09-3900 · Cited by 241
Mesa, R. A., Schwager, S., Radia, D., Cheville, A., Hussein, K., Niblack, J., Pardanani, A. D., Steensma, D. P., Litzow, M. R., Rivera, C. E., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.035 · Cited by 229
Self-citationVerstovsek, S., Kantarjian, H. M., Estrov, Z., Cortes, J. E., Thomas, D. A., Kadia, T., Pierce, S., Jabbour, E., Borthakur, G., Rumi, E., et al. (2012) · Blood · doi:10.1182/blood-2012-02-414631 · Cited by 214
Deininger, M., Radich, J., Burn, T. C., Huber, R., Paranagama, D., & Verstovsek, S. (2015) · Blood · doi:10.1182/blood-2015-03-635235 · Cited by 173
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.092155 · Cited by 170
Abdel-Wahab, O., Pardanani, A., Rampal, R., Lasho, T. L., Levine, R. L., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.82 · Cited by 134
Latimer, N. R., Abrams, K. R., Lambert, P. C., Crowther, M. J., Wailoo, A., Morden, J. P., Akehurst, R. L., & Campbell, M. J. (2014) · Medical Decision Making · doi:10.1177/0272989x13520192 · Cited by 108
Passamonti, F., Maffioli, M., Cervantes, F., Vannucchi, A. M., Morra, E., Barbui, T., Caramazza, D., Pieri, L., Rumi, E., Gisslinger, H., et al. (2014) · Blood · doi:10.1182/blood-2013-12-544411 · Cited by 99
Self-citationVerstovšek, S., Mesa, R. A., Gotlib, J. R., Levy, R. S., Gupta, V. K., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12274 · Cited by 96
Polverelli, N., Breccia, M., Benevolo, G., Martino, B., Tieghi, A., Latagliata, R., Sabattini, E., Riminucci, M., Godio, L., Catani, L., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24572 · Cited by 93
Wilkins, B. S., Radia, D., Woodley, C., Farhi, S., Keohane, C., & Harrison, C. N. (2013) · Haematologica · doi:10.3324/haematol.2013.095109 · Cited by 79
Self-citationCervantes, F., Kiladjian, J., Niederwieser, D. W., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D., Levy, R. S., Passamonti, F., Barbui, T., et al. (2012) · Blood · doi:10.1182/blood.v120.21.801.801 · Cited by 58
Self-citationVannucchi, A. M. (2011) · Hematology · doi:10.1182/asheducation-2011.1.222 · Cited by 55
Self-citationBarosi, G., Tefferi, A., Besses, C., Birgegård, G., Cervantes, F., Finazzi, G., Gisslinger, H., Grießhammer, M., Harrison, C. N., Hehlmann, R., et al. (2014) · Leukemia · doi:10.1038/leu.2014.250 · Cited by 54
Self-citationHasselbalch, H. C. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2013.876356 · Cited by 49
Korhonen, P. A., Zuber, E., Branson, M., Hollaender, N., Yateman, N. A., Katiskalahti, T., Lebwohl, D., & Haas, T. (2012) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2011.592233 · Cited by 35
Polverelli, N., Breccia, M., Benevolo, G., Martino, B., Tieghi, A., Latagliata, R., Catani, L., Nicolosi, M., Perricone, M., Romano, M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1606.1606 · Cited by 5
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
for the COMFORT-I investigators, Verstovsek, S., Mesa, R. A., Gotlib, J., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0417-z · Cited by 431
Self-citationHarrison, C. N., Schaap, N., Vannucchi, A. M., Kiladjian, J.-J., Tiu, R. V., Zachee, P., Jourdan, E., Winton, E., Silver, R. T., Schouten, H. C., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30088-1 · Cited by 339
Self-citationPrimary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26050 · Cited by 315
Metadata
- Authors
- on behalf of the COMFORT-II Investigators, Harrison, C. N., Vannucchi, A. M., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Knoops, L., Cervantes, F., Jones, M. M., Sun, K., McQuitty, M., Stalbovskaya, V, Gopalakrishna, P., & Barbui, T.
- Venue
- Leukemia
- Published
- 2016-05-23
- Volume
- 30
- Issue
- 8
- Pages
- 1701-1707
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2405712018
- Cited by
- 519
- References
- 30
- FWCI
- 31.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.